Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC). Welt, A., Lerchenmüller, C., Decker, T., Marschner, N., Salat, C., Hegewisch-Becker, S., 2013. Cancer Res 73 (24 Suppl)(P3-13-01). doi:10.1158/0008-5472.SABCS13-P3-13-01 Abstract Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder): First interim analysis of the non-interventional study PIAZA. Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Teichmann, B., Harde, J., Hasskarl, J., 2013. Onkologie 36 (suppl. 7)(P797), 241. doi:10.1159/000356365… Weiterlesen Interim analysis of a non-interventional study evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus (EVERPRO). Bergmann, L., Goebell, P., Kloß, S., Schirrmacher-Memel, S., Warnack, W., Kube, U., Scheffler, M., Doehn, C., Marschner, N., Rosé, C., Herrmann, E., 2014. Oncol Res… Weiterlesen